sublingual grass pollen extract (Oralair)
Jump to navigation
Jump to search
Introduction
Also see sublingual immunotherapy
Indications
- first sublingual allergen extract approved for treatment of allergic rhinitis & allergic conjunctivitis due to grass pollen for patients age 10-65 years[1]
Dosage
- sublingual once daily tablet
- observe first dose in clinician's office
Adverse effects
- most common
- itching & swelling in the mouth
- throat irritation
- serious: anaphylaxis (boxed warning)
Mechanism of action
More general terms
Additional terms
References
- ↑ 1.0 1.1 FDA News Release: April 2, 2014 FDA approves first sublingual allergen extract for the treatment of certain grass pollen allergies. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391458.htm